An observational study in Septic Shock, Sepsis and Peripheral Arterial Disease (PAD), sponsored by POLYSAN Scientific & Technological Pharmaceutical Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock
1,082 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
This study's planned enrollment of 60 is below the median of 110 across 407 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →POLYSAN Scientific & Technological Pharmaceutical Company is the lead sponsor of 24 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults treated in participating intensive care units for urinary- or pulmonary/respiratory-source sepsis with current or recently documented septic shock, documented lower-extremity atherosclerotic peripheral artery disease, early hemodynamic stabilization, ongoing hypoperfusion, and PiCCO Plus already in place for clinical indications. Potentially eligible participants are screened consecutively during active recruitment periods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants for whom the treating physician independently selected and actually started UNIFUZOL® at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.
Participants for whom the treating physician independently selected and actually started lactated Ringer's solution at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.
Capillary Refill Time at 6 Hours
Capillary refill time (CRT) in seconds measured using a standardized distal-finger technique. Two valid measurements are averaged; if they differ by more than 1.0 second, a third measurement is obtained and the median of three is used. The primary statistical comparison adjusts for strictly pre-infusion CRT and prespecified baseline covariates. Lower CRT is considered physiologically favorable.
Time frame: 6 hours after start (window ±60 minutes)
Thenar NIRS Reoxygenation Slope at 6 Hours
Post-occlusion reoxygenation slope (ReOx) derived from a standardized thenar near-infrared spectroscopy vascular occlusion test using a frozen common device/software/analysis algorithm. ReOx is analyzed continuously in percent StO2 per second and adjusted for pre-infusion ReOx. Higher ReOx is considered physiologically favorable.
Time frame: 6 hours after start (window ±60 minutes)
Sustained Macro-Microhemodynamic Coherent Response
Protocol-defined supportive composite outcome. This measure is reported as a single binary value (Yes/No), which is considered achieved only if ALL of the following criteria are simultaneously met: full macrohemodynamic stability, peripheral/microvascular recovery, and pulmonary/volume safety at both 6 and 12 hours. The composite is not a validated diagnostic criterion and is analyzed as supportive/exploratory.
Time frame: 6 and 12 hours after start
Change in Capillary Refill Time Over 24 Hours
Serial CRT at 60 minutes, approximately 2 hours/end of infusion, 6 hours, 12 hours, and 24 hours; analyses include continuous change and trajectory models.
Time frame: From start through 24 hours
Change in ReOx
Serial ReOx from standardized NIRS-VOT.
Time frame: From pre-infusion baseline through 24 hours
Change in De-oxygenation slope
DeOx from standardized NIRS-VOT (%/min).
Time frame: From pre-infusion baseline through 24 hours
Change in NIRS Vascular Reactivity Over 24 Hours (tissue oxygenation)
Tissue oxygenation variables (%)
Time frame: From pre-infusion baseline through 24 hours
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2028, 23 months later.
Of 202 observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
POLYSAN Scientific & Technological Pharmaceutical Company →